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bstract
In this work, three chitosan derivatives (N-carboxymethyl chitosan (CMC), N-carboxybutyl chitosan (CBC) and N-succinyl chitosan (SCC)) were
mpregnated with flurbiprofen (an anti-inflammatory drug) and timolol maleate (an anti-glaucoma drug), using a supercritical solvent impregnation
SSI) technique (and employing high pressure CO2 and CO2 + EtOH mixtures) in order to develop hydrogel-type ophthalmic drug delivery
pplications. Impregnation experiments were carried out from 9.0 up to 14.0 MPa, and at 303.0, 313.0 and 323.0 K. The resulting polymeric drug
elivery systems, as well as other polymeric samples processed in CO2, were characterized by FTIR spectroscopy and scanning electron microscopy
SEM). Drug release kinetics studies were performed for all prepared systems. The effects of impregnation pressure and temperature on the release
inetics results were studied and compared to the traditional soaking impregnation method. For the same operational conditions, results confirmed
hat the three different (chemically and physically) polymeric structures conditioned the impregnation and the drug release processes. Despite
he final released drug mass is always the result of the employed operational impregnation conditions and of the very complex relative specific
nteractions that may occur between all species present in the system (drugs, polymers, CO2 and ethanol), results showed that, for N-carboxymethyl
hitosan, the predominant effects in the impregnation process seemed to be the solubility of drugs in CO2 and in CO2 + EtOH mixtures, as well
s the swelling and plasticizing effect of CO and ethanol on the polymer. Finally, the SSI method proved to be a more efficient and “tunable”2
mpregnation process than the traditional impregnation of drugs by a soaking method. Therefore, and using this “tunable” SSI method, these
-chitosan derivatives-based ophthalmic drug delivery systems can be easily and efficiently prepared taking in consideration the desired drug
evels according to patients needs.
2007 Elsevier B.V. All rights reserved.eywords: N-chitosan derivatives; Ophthalmic drug delivery systems; Supercritical solvent impregnation (SSI); Flurbiprofen; Timolol maleate
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. Introduction
Some ocular diseases are very common in the ageing
opulation namely cataracts, glaucoma, diabetic retinopathy
nd age-related macular degeneration (AMD) [1]. Commonly,
edicines are applied on the eye surface in order to treat eye’s
uter surface diseases like infections or to provide intraocular
reatment through the cornea as glaucoma or AMD. However,
ypical topical current therapeutic procedures and formulations
resent several limitations, like poor drug bioavailability and the
ossibility of occurrence of systemic toxicity [2].
Poor ocular drug bioavailability is owed essentially to the
elative impermeability of the corneal membrane, to blinking
nd tear dynamics, and to nasolacrimal drainage. Generally, the
elivery of ocular drugs to the eye posterior segment is reduced
y the same factors that are also responsible for poor ocular
ioavailability and also by the blood-retinal barrier which lim-
ts the intravenous route in posterior drug delivery [2–4]. Poor
rug absorption across mucosal membranes is due essentially to
he drug/membrane relative hydrophobic/hydrophilic natures.
lthough, some ophthalmic drugs may present an important
herapeutic value for a specific pathology, these relative and
ifferent natures may reduce or even impede drug membrane
ermeability and, consequently, their therapeutic value is lost
5,6]. Moreover, tear dynamics and nasolacrimal duct drainage
s also the major way of entry into the circulatory system of
otent ocular drugs applied by topical administration. This may
ause undesired and toxic systemic side-effects [7–9].
Pulse-drug delivery is a recurrent but undesired pharma-
okinetic characteristic associated with topical eye drops drug
ormulations. Normally, in these systems, only less than 1–4% of
he instilled dose reaches the aqueous humor. As a consequence,
nd despite the fact of causing a potential risk of systemic tox-
city, clinicians are forced to recommend frequent drug dosing,
t high concentrations, in order to avoid the poor drug bioavail-
bility at the posterior segment of the eye [10,11]. Nevertheless,
nd despite their inherent disadvantages and associated risks,
hese conventional dosage forms account for almost 90% of the
ommercially available therapeutic ophthalmic products mostly
ecause of their favorable costs, simplicity of formulation, self-
pplication and good acceptance by patients.
To overcome these problems, and in recent years, a consider-
ble effort has been made in order to develop capable ophthalmic
ontrolled drug release systems (CDR’s), focusing essentially on
wo main objectives: (i) to find or make newer, more effective
nd safer drug molecules for the various ocular conditions and
iseases and (ii) to improve the already existing ocular dosage
orms and to exploit newer and more efficient delivery systems in
d
t
r
e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
rder to improve ocular bioavailability of already existing drug
olecules. Actual trends in ocular therapeutics and ophthalmic
rug delivery indicates that the existing dosage forms may and
robably will be substituted by new CDR’s, which can offer
mproved biopharmaceutical properties, with a better capability
o deliver therapeutic agents to the targeted receptors in the eye,
nd in a more predictable and reproducible way [12].
Presently, there are several proposed ophthalmic CDR’s
esigned to treat most of the common diseases of the eye, some
f them already are commercially available, like: enhanced top-
cal administration of water-soluble eye drops; water-insoluble
rugs in ointments; polymeric hydrogels; in situ activated gelling
ystems; mucoadhesive and bioadhesive hydrogels; colloidal
ystems, penetration enhancers; collagen shields; prodrugs and
cular inserts [2–4,7].
Hydrogels are highly swollen hydrophilic polymer networks
hich increase their volumes by absorbing large amounts of
ater or aqueous solutions [13]. Hydrogel formulations usu-
lly prolong the residence time of drugs at the absorption
ite, maintaining drug release and improving drug bioavailabil-
ty for convenient periods [14]. Different ophthalmic hydrogel
ormulations like, for example ophthacoil (a drug-loaded adher-
nt hydrogel coating on a thin metallic wire), were developed
nd are commercially available as an alternative to topical eye
rop administration for sustained drug delivery [15,16]. Other
phthalmic hydrogel-based devices like therapeutic contact
enses (TCL), intraocular lenses, glaucoma filtration implants,
eratoprostheses, intracorneal implants, scleral buckles and
iscoelastic replacement agents are also commonly used in
phthalmology [2,7,12,13,17–19]. These hydrogel devices may
e composed by synthetic (or natural) biocompatible and/or
iodegradable polymers, copolymers, polymeric blends or also
y polymeric composites.
Chitosan-based and chitosan derivatives-based hydrogels
lready showed a great potential to be used as CDR’s for sev-
ral pharmaceutical and biomedical applications [2,13,14,20,21]
ncluding ophthalmic CDR’s. Chitosan is an abundant and
atural polysaccharide which presents some interesting and
seful properties such as biocompatibility, biodegradability,
on-toxicity, adsorption and adhesion properties and the abil-
ty to interact with different substances (like hydrophilic
nd hydrophobic drugs) [13,22,23]. These characteristics are
xtremely important for medical and pharmaceutical appli-
ations, namely for the development controlled drug release
evices [13,24,25]. For ocular applications, it is also recognized
hat chitosan-based formulations present a prolonged precorneal
esidence time, an ability to increase solution viscosity and
xcellent mucoadhesive properties [26,27].
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Most of the chitosan functional biological properties are
elated to molecular weight, charge density and distribution,
egree of deacetylation and to the pH value of the media in which
hey can be placed into. Consequently, these factors can restrain
ome chitosan applications as drug delivery systems [13,14].
or example, chitosan have limited solubility at pH above 6 (the
hysiological pH of the buccal cavity) and some incompatibility
ith anionic drugs [28].
As a result, usually there is a practical necessity to develop
everal chitosan derivatives with improved solubility/non-
olubility, at different pH values, or, for example, to obtain
better permeability to anionic drugs and to avoid the unde-
ired formation of drug-polymer complexes [28,29]. This can
e done by introducing some specific chemical modifications
nto the chitosan chain molecule. These “tailored” modifica-
ions may change the polymeric solubility/non-solubility and
iodegradability/biocompatibility nature, the polymeric ability
o interact with drugs or with other biomolecules as enzymes,
or example, and the kinetics of drug release for any new or
articular envisaged controlled drug delivery application. For
xample, Sandri et al. [28], studied different chitosan deriva-
ives as acyclovir penetration enhancers adding the drug to
everal modified chitosans: 5-methyl-pyrrolidinone chitosan
MPC), low molecular weight chitosans, a partially reacety-
ated chitosan and chitosan hydrochloride. In this study, MPC
resented the best mucoadhesive and penetration/permeation
nhancement properties. Thanou et al. [29] studied, the use
f high viscosity chitosan (HCS) and low viscosity (LCS) chi-
osan as well as mono-N-carboxymethyl chitosan (MCC) with
ow and high grade viscosities (LMCC and HMCC). On other
ork, the permeation and adsorption of low molecular weight
eparin (LMWH) was increased using N-carboxymethylated
hitosan via intestinal epithelia [30]. Other chitosan deriva-
ive, trimethyl chitosan chloride (TMC), showed an increased
eptide intestinal absorption and bioavailability for buserelin
nd octreotide analogs across intestinal epithelia [30]. In addi-
ion to N-carboxymethyl chitosan (CMC), other N-carboxyalkyl
hitosans like N-carboxybutyl chitosan (CBC) and succinyl chi-
osan (SCC) (Fig. 1) had been studied as polymeric drug carriers
31–33].
Polymeric dispersed drug CDR’s are usually prepared by two
onventional methods. A first method consists in mixing the
rug, or drugs, in the polymer synthesis reactive mixture, con-
aining monomers, co-monomers, cross-linkers, initiators, etc.
rugs can be soluble or insoluble in this mixture. Then, the
d
p
m
m
Fig. 1. Structural formula of employed chitosan derivatives: (a) N-carboxymecal Fluids 44 (2008) 245–257 247
esulting mixture is polymerized, for example, by a thermal or
hotochemical route. A second method consists in immersing
nd soaking the polymeric particles/articles, previously syn-
hesized, into a solution, or dispersion, containing the drugs
o impregnate/infuse. Usually an aqueous solution, or disper-
ion, is used but organic solutions or dispersions can also be
mployed, depending essentially on drug and polymer solubil-
ty or on other considerations like, for example, solvent toxicity
nd solvent facility to be removed/evaporated [34–39]. How-
ver, these methods present several disadvantages, like the use
f sometimes toxic organic solvents, which have to be removed
y heating, undesired drug reactions, drug and polymer photo-
hemical and thermal degradation, low incorporation yields and
eterogeneous drug dispersion.
Drugs may also be impregnated by dissolving them in com-
ressed high volatile fluids like supercritical carbon dioxide, at
emperatures and pressures near or above their critical temper-
tures and pressures, and contacting the resulting mixture with
he polymeric matrixes to be infused. In these conditions, the
ompressed fluid can act also as a swelling and plasticizer agent
or polymers, helping drugs’ diffusion into them. This happens
ecause, and despite the usually low polymer solubility in CO2,
he sorption and solubility of CO2 in some polymers is consider-
bly high, promoting polymer swelling and changing polymeric
echanical properties by a plasticization effect [40–42].
This recent technique, presents several advantages for the
evelopment of drug impregnated polymeric materials which
an be used as drug delivery systems for many biomedi-
al applications. It is called supercritical solvent impregnation
SSI) [40–43] and permits the drug impregnation of a great
art of polymeric matrixes. Furthermore, some interesting
ydrophobic drugs, which can not be impregnated by aque-
us solution/suspension soaking, can be incorporated by this
ethod. Drug loading and drug depth penetration can be con-
idered as a “tunable” process since it can be performed by
ontrolling the depressurization step (which can be performed
t several rates), the time of impregnation or by changing
he solvent density (and consequently the drug solubility in
t) by pressure and temperature control, in opposition of con-
entional impregnation processes [40–42]. Furthermore, and in
ost cases, it can be carried properly in order to not alter and/oramage polymeric materials physical, chemical, and mechanical
roperties and without degrading drugs, additives and poly-
ers. It also may permit to have previously prepared polymeric
atrixes and, later, impregnate them with the desired drugs,
thyl chitosan; (b) N-carboxybutyl chitosan and (c) N-succinyl chitosan.
248 M.E.M. Braga et al. / J. of Supercritical Fluids 44 (2008) 245–257
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CMC + timolol maleate.
Average depressurization average rates were 0.29 ±
0.01 MPa/s, for polymer + flurbiprofen systems, and 0.29 ±
0.02 MPa/s for polymer + timolol maleate systems. HigherFig. 2. Structural form
ccording to desired applications and patients’ needs and leaving
o harmful solvent residues.
Several ophthalmic drugs were already incorporated into
olymeric matrixes with the intention of preparing ophthalmic
DR’s systems and are reported in the literature: for exam-
le, cortisone and retinol [44], ibuprofen [45], pilocarpine [46]
nd indomethacin [47]. Some systems were already prepared
sing the SSI technique and using CO2 as the high pressure
olvent [48,45,49]. Some ophthalmic drugs as timolol maleate
nd flurbiprofen, a beta adrenergic blocker, and, a non-steroidal
nalgesic/anti-inflammatory, respectively (Fig. 2) had also been
sed as active principles in several polymeric-based (acrylates
nd chitosan/carbopol mixtures, respectively) ocular CDR’s pre-
ared by reverse phase evaporation [50] and by quasi-emulsion
olvent diffusion technique [51].
The solubility of these two solid drugs was already measured
n carbon dioxide. The maximum solubility for flurbiprofen
as found to be 0.90 g/L, at 323 K and 234 bar [52]. For
imolol maleate the maximum CO2 solubility was determined
s 0.56 g/L [53]. The minimum amount of flurbiprofen to be
ept in the eye must be, at least, 0.03–0.15g, the therapeutic
imit in order to prevent and treat inflammatory processes. Its
hronic toxicity is 5 mg/(kg day) for 26 weeks [54], based on
ata obtained at clinical essays in baboons. For timolol maleate,
he maximum recommended therapeutic dose (MRTD) is
mg/(kg-bw day) [55].
The main objectives of this work were to study the impreg-
ation of two ophthalmic drugs (flurbiprofen and timolol
aleate) into three chitosan derivatives: N-carboxymethyl chi-
osan (CMC), N-carboxybutyl chitosan (CBC) and N-succinyl
hitosan (SCC), using the supercritical solvent impregna-
ion (SSI) methodology employing high pressure CO2 and
O2 + EtOH mixtures, in order to prepare hydrogel-type drug
elivery systems for ophthalmic applications. Other goals were
o study the pressure and temperature effects on the resulting
DR’s systems and to compare the employed SSI method with
he conventional polymer soaking method.
. Materials and methods.1. Chemicals
The three chitosan derivatives used in this work: N-carboxy-
ethyl chitosan (CMC), N-carboxybutyl chitosan (CBC) and
F
r
b
8f impregnated drugs.
-succinylchitosan (SCC) were prepared according to Silva
56], Fig. 1. Employed ophthalmic drugs were: flurbiprofen
97%, Sigma–Aldrich, CAS [5104-49-4], Germany) and timolol
aleate (≥98%, Sigma–Aldrich, CAS [26921-17-5], Germany),
ig. 2. Employed solvents were: carbon dioxide (99.998%, Prax-
ir, Spain) and ethanol (99.8%, Riedel-de-Hae¨n). Physiological
erum (sodium chloride isotonic solution, pH 6, 154 mEq for
a+ and Cl−, Osm ∼285 mOsm/kg, Fresenius Kabi, Portugal)
as used as drug release media.
.2. Impregnation methods
The employed supercritical impregnation apparatus is
escribed by Patent EP 1 611 877 A1 (Unit I), and it is presented
t Fig. 3 [57]. This unit is comprised by a compressed air-
perated CO2 liquid pump, a visual stainless steel impregnation
ell (with approximately 10 cm3 of internal volume), equipped
ith sapphire windows, a thermostatic controlled water bath and
magnetic stirring plate as an auxiliary tool to homogenize the
igh pressure mixture (drug + CO2 or drug + CO2 + cosolvent).
thanol (EtOH), 5%, mol, was used as the cosolvent and with the
ntention of increase timolol maleate’s solubility in supercritical
arbon dioxide [53]. Several supercritical solvent impregnation
SSI) experiments were performed in order to study the effects
f operational temperature at ∼303, 313 and 323 K and pressure
rom ∼9 up to 14 MPa) for the systems CMC + flurbiprofen andig. 3. Schematic diagram of the experimental supercritical impregnation appa-
atus: (1) CO2 reservoir; (2) high pressure CO2 pump; (3, 9) valves; (4) water
ath; (5) high pressure stainless steel impregnation cell; (6) magnetic stirrer; (7,
) thermometer and pressure transducer and (10) glass trap.
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epressurization rates may cause the “explosion” of polymeric
amples and, consequently, may destroy their structures.
The SSI method consists in introduce the CO2 into the sealed
igh pressure impregnation cell, previously charged with the
olymeric sample (around 0.004–0.015 g of polymer), the drug
and the cosolvent, when used), at the pre-established pro-
ess temperature and pressure. Magnetic stirring was always
mployed in order to solubilize and homogenize the drug in the
ompressed fluid (CO2 or mixture of CO2 + EtOH). The amount
f drug was established taking in consideration its solubility (sat-
rated environment) at the operational conditions. The amount
f added cosolvent was also calculated taking into consideration
he desired cosolvent concentration and the operational temper-
ture and pressure conditions. SSI experiments were carried out
uring 1 h. After this period, the compressed fluid, or the mix-
ure of compressed fluid and cosolvent, was removed by slow
xpansion in order not to alter or damage the polymeric sam-
les. Impregnated samples were then recovered in a dry final
tate.
Conventional drug soaking experiments were performed in a
lass vial, containing the polymeric sample to be impregnated,
uring 1 h, in saturated drug + physiological serum solutions and
t ambient conditions (0.1 MPa, 294 K).
.3. Impregnated drug amounts
The amounts of impregnated drugs were quantified gravi-
etrically, before and after impregnation experiments, and
ompared to the results obtained by the drug release kinetics
pectrophotometric method (to be described further on). The
olymeric flurbiprofen and timolol maleate residual contents
after drug release experiments) were quantified by fluorine
nd sulphur, respectively, analysis using Ion Chromatography
Waters, 431 model, USA) with conductivity detector (Milli-
ore, USA), IC-Pak A anions column and borate/gluconate as
luent, at 2.93 MPa, conductivity of 319S and flow rate of
mL/min.
.4. In vitro drug release kinetics
Drug release kinetics studies were performed for all prepared
ystems using a spectrophotometer (Jasco, models 530 and 550,
apan), at 247 and 298 nm, for the release of flurbiprofen and
imolol maleate, respectively. Release experiments were carried
ut during 8 h, in order to simulate the envisaged ophthalmic
se.
Impregnated polymers were immersed in physiological
erum, at 310 K, and an aliquot (1.6 mL) of the released drug
olution was removed and analyzed, with or without renovation
f the release medium with fresh serum. The release medium
enovation was done, for each experimental release point, by
emoving an aliquot (1.6 mL) for UV analysis and by adding
he same volume of fresh serum to the release medium. Drug
oncentration was calculated using previously determined drug
alibration curves [57–59].
The operational central point of experiments was considered
o be 11 MPa and 313 K (obtained for CMC + timolol maleate
r
C
fl
scal Fluids 44 (2008) 245–257 249
xperiments) and, at these conditions, triplicate assays were per-
ormed in order to obtain the experiments standard deviation
±0.012 mg of drug/mg of polymer).
.5. Degradation experiments
Non-impregnated CMC samples were also tested in terms
f their ability to degrade over time in the physiological serum
olution. CMC samples were pressurized, for 1 h, with super-
ritical CO2 at 12 MPa and 313 K. These samples were then
mmersed and maintained in physiological serum for 168 h (one
eek). After this period, the physiological serum was analyzed
pectrophotometrically (at 200–800 nm) in order to detect the
resence of substances generated from polymer degradation
nd/or solubilization.
.6. Estimation of diffusion kinetics coefficients
Drug release kinetics coefficients were estimated from the
urbiprofen/polymers drug release kinetics studies. Curves were
tted using Eq. (1), where Mt and M∞ represent the amounts
f flurbiprofen released at time t and after infinite time, respec-
ively, n is the diffusion exponent and k the diffusion kinetic
onstant [60,61].
Mt
M∞
= k.tn (1)
.7. Sample characterization
Obtained controlled drug delivery systems were chemi-
ally and optically characterized by FTIR-ATR spectroscopy
Magma-IR Spectrometer 750, Nicolet Instrument Corp., Wis-
onsin, USA; ATR, Golden Gate MK II, Specac, USA) DTGS
Br detector, at 32 scans and 4 cm−1 of resolution) and by
canning Electron Microscopy (SEM) (Jeol, JSM-5310 model,
apan), at 25 kV. Samples were coated with gold, approximately
00 A˚, in an argon atmosphere, and analyzed before and after
he polymer impregnation experiments.
. Results and discussions
The drug release triplicate assays, which were performed at
n operational central point (11 MPa and 313 K) for the timolol
aleate + CMC system, presented in vitro drug release average
alues with a curve amplitude of 3% (in mass) until the sec-
nd experimental point. After this point, curve amplitude was
lmost constant, 1–2% (in mass). These amplitude values were
onsidered to be valid for all studied systems (Table 1).
Fig. 4 shows the accumulated flurbiprofen mass release pro-
les for the three employed chitosan derivatives (CMC, CBC
nd SCC), impregnated for 1 h at 12 MPa and 313 K by SSI.
s shown, and after 8 h of release studies, the accumulatedeleased amount of flurbiprofen was found to be higher for
MC, followed by SCC and CBC (0.125, 0.081 and 0.053 mg
urbiprofen/mg polymer, respectively). These in vitro release
tudies were performed without the renovation of the releasing
250 M.E.M. Braga et al. / J. of Supercritical Fluids 44 (2008) 245–257
Table 1
Accumulated drug release results in physiological serum, obtained after 8 h of drug release from SSI and soaking flurbiprofen and timolol maleate impregnated
chitosan derivatives (CMC, CBC and SCC). For Flurbiprofen, drug release was performed without physiological serum renovation. For timolol maleate, drug release
was performed with physiological serum renovation
Impregnation process Timolol maleate (5%) (mg/mg polymer)
∼0.1 (MPa) 9 (MPa) 10 (MPa) 11 (MPa) 12 (MPa) 13 (MPa) 14 (MPa)
CMC polymer
SSI (30 ◦C) – 0.443 0.541 0.587 0.528 0.478 0.449
SSI (40 ◦C) – 0.394 0.462 0.531 ± 0.012 0.550 0.800 0.849
SSI (50 ◦C) – 0.086 0.203 0.461 0.590 0.527 0.445
Soaking 0.674 – – – – – –
Impregnation process Flurbiprofen (mg/mg polymer)
CMC polymers CBC polymers
12 (MPa)
SCC polymers
12 (MPa)∼0.1(MPa) 9 (MPa) 10 (MPa) 11 (MPa) 12 (MPa) 13 (MPa) 14 (MPa)
SSI (30 ◦C) – 0.080 – – – – – – –
SSI (40 ◦C – 0.035 0.035 0.097 0.125 0.147 – 0.053 0.081
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oSI (50 ◦C) – 0.017 0.043 0.112
oaking 0.074 – – –
edia (without the addition of a “fresh” volume of physiologi-
al serum). All impregnated samples presented almost the same
rug release profile, a typical biphasic release pattern: (i) a dif-
usional period with an initial increase probably as a result of the
apid release caused by drugs deposited on and near the poly-
eric surface and which is related to the total surface of polymers
nd/or to its high porosity; (ii) a swelling phase, a period that
ccurs before the disintegration/dissolution of the polymers
which was not observed, because the degradation/solubilization
ests indicated that the physiological serum solution did not
egrade or solubilize the employed polymers after 168 h of con-
act, at ambient conditions). However, while flurbiprofen release
rom CBC reached the equilibrium at approximately 30 min; for
MC and SCC around 2.5 h were required to reach equilibrium.
The observed initial burst release profiles can be an indication
hat the impregnated drug was mainly located at the polymer sur-
ace or near it. And the different initial profiles obtained would
hen be the result of the different impregnation efficiencies due
o the different interactions between CO2, drugs and the three
mployed chitosan derivatives. Short impregnation periods can
lso be responsible for low depth impregnation but the impregna-
ion duration was kept constant for these experiments. However,
ig. 4. Accumulated flurbiprofen mass released from chitosan derivatives,
mpregnated at 12 MPa and 40 ◦C by SSI: CMC;  SCC and  CBC.
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ifferent release profiles can also be due to other factors related
ith the release experiments and not just to the impregnation
rocess like, for example, polymer/drug/release medium phys-
cal and chemical properties and interactions and to polymer
welling. Therefore, this is an evidence that, at the same impreg-
ation and release conditions, the three different (chemically
nd physically) polymeric structures somehow conditioned the
mpregnation and the drug release processes.
The conventional soaking method, employed for the same
ystem (CMC + flurbiprofen) and soaking the polymeric sample
or 1 h at ambient conditions (∼0.1 MPa and 294 K), showed an
ccumulated released drug amount of 0.074 mg flurbiprofen/mg
f CMC (Table 1), which is almost half of the observed release
or the sample impregnated by SSI at 12 MPa and 313 K. How-
ver, this observed more efficient SSI impregnation does not
ccur for all the employed operational temperature and pressure
onditions and this subject will be discussed in detail further
n. Table 1 also presents other results which show that, for the
MC derivative, SSI is a “tunable” impregnation process, i.e.,
arying the operational pressure and temperature conditions will
esult in the impregnation of different drug amounts which will
ead to different drug released amounts (from 0.017 to 0.147 mg
f flurbiprofen/mg of CMC). This is an evident advantage of
he SSI technique. Furthermore, in some cases and for strongly
ydrophobic drugs, it is not possible to use drug aqueous soaking
olutions and the use of organic solvents is not recommendable
or the development of CDR’s applications.
Fig. 5 shows the absolute flurbiprofen mass released, as a
unction of release time, for the three used chitosan derivatives. It
an be seen that the diffusional period may be extended over time
ntil the released drug mass become almost constant: around 1 h
∼1–2g), 3 h (∼3–5g) and 4 h (∼3–6g), for CBC, SCC and
MC, respectively, and above the flurbiprofen therapeutic limit.
he knowledge of these values is very important to develop effi-
ient CDR devices, capable to keep drug concentrations between
herapeutic and toxic limits. The mass variation showed in the
M.E.M. Braga et al. / J. of Supercriti
Fig. 5. Flurbiprofen mass released from chitosan derivatives, impregnated at
12 MPa and 40 ◦C by SSI: () CMC; () SCC and () CBC.
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Sig. 6. FTIR analysis of chitosan derivatives before impregnation: (—) CBC;
—) SCC and (···) CMC.
oomed part of Fig. 5 is still due to small fluctuations in drug
elease and not to any experimental uncertainties related to the
ethod detection limit.
FTIR analysis (Fig. 6) shows the different spectrum pro-
les for the three chitosan derivatives. A characteristic peak for
hese polymers appears at the same wavelength (1541 cm−1)
nd is probably indicative of the NH2 group substitution [62].
1
r
r
able 2
lurbiprofen drug release kinetic parameters for impregnated samples at 40 ◦C: CMC
mpregnation process Polymers
CMC CBC
SI (MPa) n k r2 n
.0 0.87 1.88 0.98 –
0.0 0.64 1.49 0.98 –
1.0 1.09 2.19 0.98 –
2.0 1.20 1.79 0.99 0.57
3.0 0.75 1.84 0.96 –
oaking 0.64 1.19 0.99 –cal Fluids 44 (2008) 245–257 251
TIR analysis is not conclusive but it is an indication of the
hemical differences between the three synthesized chitosan
erivatives. Besides, the different attained substitution degrees in
hese derivatives must be also taken in consideration: for exam-
le, CMC may have more probability to be di-substituted (which
ill increase the number of polymer carbonyl groups) [63] lead-
ng to higher interactions with CO2 and, consequently, to higher
O2 sorption and polymer swelling, contrarily to CBC and
CC. Because impregnation yields are also strongly dependent
n these factors (sorption and swelling) this can be a possible
xplanation for the higher amounts of impregnated flurbipro-
en observed for CMC when compared to CBC and SCC at
he same operational impregnation conditions (see Table 1 and
ig. 4).
Table 2 shows the calculated values for diffusional kinetic
onstants (k) and diffusional coefficients (n) for the kinetics
f flurbiprofen release from the three chitosan derivatives, as
function of operational impregnation pressure. The n value is
epresentative of the transportation mechanism and, for the stud-
ed systems, at 12 MPa, is higher for CMC followed by SCC and
BC (being 1.20, 0.86 and 0.57, respectively).
These values are in good agreement with the release curves
resented at Fig. 4. All systems present a Non-Fickian behav-
or. Comparing the n values, as a function of pressure for the
MC + flurbiprofen system, it is possible to observe an increase
t 11 and 12 MPa, showing that, in some way, the impregnation
perational pressure has influence on the system. The diffusional
inetic constant (k), which usually defines the characteristics of
polymeric network system, is different for all polymers (at
2 MPa) and follows the order CMC > CBC > SCC (around 1.8,
.5 and 1.2, respectively). Higher diffusional kinetic constant
alues can be an indication of the existence of more favorable
nteractions between the polymer and the drug (flurbiprofen) in
he physiological serum medium [31].
Fig. 7 shows drug release assays, at 313 K and at 9, 12 and
3 MPa, performed with and without drug release media (serum)
enovation. The experiments with renovation of the drug release
edia with fresh serum (1.6 ml) were done in order to simulate
he in vivo eye conditions in terms of tear renovation, evapora-2 MPa, the difference (in terms of released mass) between the
elease experiments with serum renovation and without serum
enovation was around 7%, with a slightly increase for the begin-
, CBC and SCC; (n) diffusion exponent and (k) diffusion kinetic constant
SCC
k r2 n k r2
– – – – –
– – – – –
– – – – –
1.52 0.99 0.86 1.19 0.98
– – – – –
– – – – –
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Fig. 7. Accumulated flurbiprofen mass released from CMC, impregnated at
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cation that the CO2 + drug high pressure mixture swelled and
F
b0 C by SSI, with serum renovation (SR) and without serum renovation: ()
0 bar, (©) 90 bar, SR; () 120 bar, () 120 bar, SR and ( )130 bar, (1)30 bar,
R.
ing of the 12 MPa release kinetics. At 13 MPa, the difference
etween the two drug release methodologies was around 0.8%,
or the first release point, and 0.1% for all the rest.Fig. 8 shows the three chitosan derivatives surface observed
y SEM before impregnation (I), after pressurization/treatment
ith CO2 (II) and impregnated with flurbiprofen by SSI
p
c
i
ig. 8. Chitosan derivatives samples (CMC, CBC and SCC) observed by SEM before th
y SSI (III), at 12 MPa and 40 ◦C.cal Fluids 44 (2008) 245–257
III), at 12 MPa and 313 K. CMC shows a pattern of quasi-
arallel smooth sheets, in several layers, which seem to be
ust slightly changed after the CO2 treatment and also after
he flurbiprofen impregnation. Before impregnation and CO2
reatment, CBC presents a kind of twisted flexible sheets pat-
ern (in layers) and, after pressurization and impregnation, these
heets seem to become more twisted, like interlaced wires.
inally, SCC shows an interlaced wires pattern, which seems
o become more interlaced after CO2 treatment and impregna-
ion. These observations are a clear confirmation of the well
nown high pressure/supercritical CO2 plasticizing effect on the
nal morphological characteristics of these polymeric samples
hich, consequently, will influence their physical, mechanical
nd thermal properties. These effects (as well as others like
nduced crystallization) are already referred in the literature
41,42,64,65]. Finally, at Fig. 8, it is also possible to observe
urbiprofen’s particles deposited on the surface of the chitosan
erivatives. Despite the fact that only the deposited surface par-
icles are visible, because the obtained drug release profiles and
he notorious effect on samples’ morphology (a strong indi-lasticized these samples), we may presume that, with some
onfidence, flurbiprofen was also precipitated and impregnated
nto the three chitosan derivatives.
e impregnation (I); pressurized with CO2 (II) and impregnated with flurbiprofen
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(ig. 9. (A) Flurbiprofen partition coefficient for CMC as a function of CO2 de
SI: () 30 ◦C; () 40 ◦C and (×) 50 ◦C. Flurbiprofen solubility in CO2: (—) 3
Fig. 9(A) shows the flurbiprofen/CMC partition coefficient
s a function of CO2 density while Fig. 9(B) shows the accu-
ulated flurbiprofen mass released (in absolute terms), also in
unction of CO2 density, at 303, 313 and 323 K. In both figures
t is also represented the flurbiprofen’s solubility in CO2 and, as
xpected, it is clear that the correlated flurbiprofen solubility in
O2 increases with the CO2 density for the three experimental
olubility temperatures. Flurbiprofen is known to have a rela-
ively high solubility in supercritical CO2 and the experimental
urbiprofen’s solubility in supercritical CO2 was obtained and
orrelated by authors [52,53,64,66]. Fig. 9(A) shows that the
urbiprofen’s partition coefficient (FBPp/FBPs ratio) decreases
ith the increase of the CO2 density. However, Fig. 9(B) shows
hat, in general terms and as expected, flurbiprofen absolute
mpregnated mass tends to increase with the CO2 density. This
s due to above referred drug solubility increment and, probably,
o the higher swelling and plasticizing effects promoted by high
ensity supercritical (or liquid) supercritical carbon dioxide.
e do not possess experimental data on these phenomena buthey are recognized to be very common and important on these
rocesses and are abundantly reported in literature [65,67,69].
For example, at 303 K and 9 MPa, the drug + supercritical
O2 mixture is at a high pressure liquid state, which corresponds
a
i
i
w
ig. 10. Accumulated timolol maleate mass released from CMC impregnated by CO
) 40 ◦C and (×) 50 ◦C.(B) Accumulated flurbiprofen mass released from CMC impregnated by CO2
; (—) 40 ◦C and (···) 50 ◦C.
o a high density liquid state (thus promoting drug solubility in
he high pressure phase). At the same pressure and at 313 K, the
olymer is in the presence of a high pressure supercritical phase
n which CO2 densities are lower than at 303 K but higher than
t 323 K. As a consequence, flurbiprofen was impregnated in a
maller extent than at 303 K and in a higher extent than at 323 K.
owever, this does not happen for all experimental pressures
for example at 11 and 12 MPa) which may indicate that other
henomena, and not just drug solubility, are involved in the
rocess. In fact, the global impregnation process will always
e the result of the relative specific interactions that may occur
n the system: CO2-drug interactions (which controls drug
olubility in CO2), polymer-CO2 interactions (which controls
O2 solubility in the polymer and, consequently, swelling
nd plasticization) and drug-polymer interactions (which
ontrols solubility/compatibility of the drug in the polymer).
dditionally, induced crystallization of the polymeric substrate
an also influence the overall impregnation process. [65,67-69].
owever, a reasonable approach is to consider that the oper-tional (P and T) conditions will not affect the drug-polymer
nteractions as much as it will affect the two other possible
nteractions (the drug-polymer system – flurbiprofen/CMC –
as the same for all these represented systems and pressure and
2 + EtOH (5% mol) SSI, as a function of pressure and CO2 density: ()30 ◦C;
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emperature are not expected to strongly influence the specific
nteractions between these two solids). Thus, we may consider
hat, in fact, the predominant effects in the impregnation
rocess may be the solubility of the drug in CO2 as well as
he CO2 swelling and plasticizing effect on the polymers. On
his type of polymers, induced crystallization by supercritical
O2 is not supposed to occur. Another important operational
ariable could be the system depressurization rate but it was
ept constant for all studied systems.
So far, all the presented impregnated flurbiprofen amounts
ere determined by the drug release kinetics results (corre-
ponding to the maximum of the released flurbiprofen accumu-
ated mass). To verify these results, the amounts of impregnated
urbiprofen were also attempted to be quantified gravimetrically
weighing samples before and after impregnation experiments).
owever, experimentally, it was very difficult to measure gravi-
etrically these amounts because of the relatively low drug
mounts involved and to the possibility of occurrence of some
ass loss. This mass loss could be explained by the CO2
xtraction of any chemicals (or of CO2 soluble low molecular
eight polymeric chains) still present in the polymeric matrixes.
ther explanation could be the removal of small solid polymer
articles, pulled out of the system during depressurization. Flur-
iprofen quantification by ion chromatography analysis also did
ot lead to satisfactory results because the very low flurbiprofen
esidual contents may induce high errors in results.
Fig. 10 shows the accumulated timolol mass released from
MC, impregnated by SSI using CO2 + EtOH, as a function
f operational pressure and of CO2 density. These results are
lso presented in Table 1. All release experiments were car-
ied out with renovation of the drug release media. The highest
mpregnated amount of timolol maleate was attained at 313 and
4 MPa (0.849 mg drug/mg polymer). For this system, and for all
mpregnation operational temperatures and pressures, after the
wo initial hours of drug release experiments (with serum ren-
vation), the released mass of timolol maleate was found to be
lmost constant over time (5–10g) for the next 6 h of release.
s can be seen, just for the 313 K isotherm there is a general
endency for the maximum impregnated timolol maleate mass
ncrease with the operational pressure and with the CO2 density.
or 303 and 323 K isotherms, the impregnated mass increases
ith pressure and CO2 density, passes through a maximum
around 0.5–0.6 mg of drug/mg of polymer) and then decreases.
i
i
s
i
ig. 11. Temperature effects of SSI-CO2 + EtOH timolol maleate impregnation on C
C) 50 ◦C.cal Fluids 44 (2008) 245–257
possible explanation is that, probably, at higher densities, the
nteractions between the solute and the mobile phase increased
nd are detrimental to the bonding forces between the solute and
he polymeric matrix, thus leading to lower impregnation yields.
ut this did not occur for the 313 K isotherm. As already referred
or the flurbiprofen system, the final partitioning of the solute
etween the mobile phase and the solid matrix will be the result
f the relative strength of all binary interactions involved in the
ystem. And, for timolol maleate, the high pressure mobile phase
as an extra compound, the cosolvent (ethanol), thus increasing
ven more the system complexity. It is well known from lit-
rature that drug solubility in CO2 will increase when using a
osolvent with the same polar characteristics of the drug. It is
lso known that the same can happen with the polymer solubil-
ty in CO2 and the CO2 solubility in polymers. However, we do
ot have any information regarding these cosolvent effects on
ll the possible involved interactions that may be controlling the
mpregnation efficiency.
Fig. 11 shows the surface SEM micrographs of CMC impreg-
ated with timolol maleate by SSI-CO2 + EtOH, at 303 K (A),
13 K (B) and 323 K (C), and at 12 MPa. As can be seen, there
s a large amount of drug deposited at polymer surfaces. It also
ooks like the drug is “plasticized”, forming films on the polymer
urface. This can be due to a cosolvent (ethanol) effect on the
eposition of drug particles during depressurization. Unfortu-
ately, timolol maleate is almost insoluble in high pressure CO2
nd we were unable to perform timolol impregnation exper-
ments without the ethanol addition. Moreover, the presence
f ethanol seems to have a strong influence on the amount of
mpregnated drug.
When we compare the relative amounts of released
rugs (mg drug/mg polymer) between flurbiprofen and timolol
aleate, Fig. 12(A) and (B), we can see that timolol maleate was
mpregnated in higher extents than flurbiprofen, despite the fact
hat it is much less soluble in CO2 than flurbiprofen [52,53].
or both drugs, it is also clear the already referred pressure-
riven “tunable” character of the SSI method which constitutes
n advantage over the soaking method.
Like in the CMC + flurbiprofen case, in this system the drug
mpregnated final mass will also be the result of the operational
mpregnation conditions and of the very complex relative
pecific interactions that may occur between all species present
n the system: drugs, polymers, CO2 and, now a cosolvent
MC at 12 MPa. Surface samples observed by SEM: (A) 30 ◦C; (B) 40 ◦C and
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Fig. 12. Accumulated flurbiprofen (A) and timolol maleate (B) mass released from im
() 13 MPa and () 14 MPa; and (©) ∼0.1 MPa soaking at 25 ◦C.
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Aig. 13. FTIR analysis of timolol maleate CO2 + EtOH (5% mol) SSI impreg-
ated CMC: (—) CMC before SSI; (—) CMC + timolol maleate after SSI (at
13 K and 12 MPa) and (···) timolol maleate.
ethanol). Thus, ethanol could be not just improving timolol
aleate solubility in CO2 but also increasing the solubility
f the high pressure phase (containing also CO2 and timolol
aleate) in the CMC polymeric matrix, as well as improving
he compatibility, swelling and plasticizing power of this phase.
Like for flurbiprofen impregnation, only the surface
eposited particles/films are visible on micrographs. However,
nd due to the obtained drug release profiles and to the noto-
ious swelling and plasticizing effects observed on polymeric
amples’ morphology, in this case we may consider that timolol
aleate was also precipitated and impregnated inside the three
hitosan derivatives. Samples loaded with timolol maleate were
lso analyzed by FTIR and, in Fig. 13, it is possible to observe the
wo spectra profiles, corresponding to the polymer (CMC) with
nd without impregnated drug. The individual FTIR spectrum
or timolol maleate confirmed this result. Furthermore, sulphur
uantification (performed by ion chromatography analysis) per-
itted to quantify the amount of timolol maleate still present
n the polymeric matrix after the drug release experiments in
hysiological serum (1.54 ± 0.32% of total impregnated mass,
ith 98.46 ± 0.32% of total released drug mass).. Conclusions
In this work three chitosan derivatives (N-carboxymethyl chi-
osan, N-carboxybutyl chitosan and N-succinyl chitosan) were
P
a
(pregnated CMC SSI at 40 ◦C: () 9 MPa; () 10 MPa; () 11 MPa;(×) 12 MPa;
mpregnated with flurbiprofen and timolol maleate, using a SSI
echnique (and employing high pressure CO2 and CO2 + EtOH
ixtures) in order to try to develop hydrogel-type ophthalmic
rug release systems. Impregnation experiments were car-
ied out from 9.0 up to 14.0 MPa, and at 303.0, 313.0 and
23.0 K. The resulting polymeric drug delivery systems, as
ell as other polymeric samples processed in CO2, were
haracterized by FTIR spectroscopy and Scanning Electron
icroscopy (SEM). Drug release kinetics studies were per-
ormed for all prepared systems. The effects of impregnation
ressure and temperature on the release kinetics results were
tudied and compared to the traditional soaking impregnation
ethod.
For the same operational conditions, results confirmed that,
s expected, the three different (chemically and physically)
olymeric structures conditioned the impregnation and the
rug release processes. Furthermore, and even though the final
mpregnated drug mass is always the result of the employed
perational impregnation conditions and of the very com-
lex relative specific interactions that may occur between all
pecies present in the system (drugs, polymers, CO2 and
thanol), results showed that, for N-carboxymethyl chitosan,
he predominant effects in the impregnation process seemed
o be the solubility of drugs in CO2 and in CO2 + EtOH
ixtures, as well as the swelling and plasticizing effect of
O2 and ethanol on the polymer. Finally, the SSI method
roved to be a more efficient and “tunable” impregnation pro-
ess than the traditional impregnation of drugs by a soaking
ethod.
Therefore, and using this “tunable” SSI method, these N-
hitosan derivatives-based ophthalmic drug delivery systems
an be easily and efficiently prepared taking in consideration
he desired drug levels according to patients needs.
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